Total Revenue
Merck & Co. Total Revenue decreased by 0.7% to $16.29B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.9%, from $15.53B to $16.29B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 7.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.40B | $13.15B | $12.07B | $15.90B | $14.59B | $14.96B | $13.83B | $14.49B | $15.04B | $15.96B | $14.63B | $15.78B | $16.11B | $16.66B | $15.62B | $15.53B | $15.81B | $17.28B | $16.40B | $16.29B |
| QoQ Change | — | +15.4% | -8.3% | +31.8% | -8.2% | +2.5% | -7.5% | +4.8% | +3.8% | +6.2% | -8.3% | +7.8% | +2.1% | +3.4% | -6.2% | -0.6% | +1.8% | +9.3% | -5.1% | -0.7% |
| YoY Change | — | — | — | — | +28.0% | +13.7% | +14.6% | -8.9% | +3.0% | +6.7% | +5.8% | +8.9% | +7.2% | +4.4% | +6.8% | -1.6% | -1.9% | +3.7% | +5.0% | +4.9% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Keytruda | $14.54B | $14.86B | $15.67B | $14.41B | $15.91B | $16.28B | $16.68B | $7.91B |
| Gardasil/Gardasil 9 | $4.96B | $4.61B | $3.10B | $2.65B | $2.25B | $3.50B | $2.06B | $1.07B |
| Livestock | $1.67B | $1.77B | $1.78B | $1.85B | $1.92B | $2.05B | $1.98B | $1.06B |
| Other pharmaceutical | $1.15B | $1.28B | $1.44B | $1.46B | $1.17B | $1.91B | $1.30B | $775.00M |
| ProQuad/M-M-R II/Varivax | $1.23B | $1.41B | $1.19B | $1.08B | $1.22B | $1.37B | $1.24B | $538.00M |
| Winrevair | $140.00M | $299.00M | $399.00M | $560.00M | $671.00M | $720.00M | $935.00M | $525.00M |
| Bridion | $910.00M | $840.00M | $898.00M | $882.00M | $922.00M | $878.00M | $999.00M | $472.00M |
| Januvia | $809.00M | $556.00M | $465.00M | $1.10B | $743.00M | $764.00M | $604.00M | $367.00M |
| Alliance revenue - Lynparza | $635.00M | $675.00M | $728.00M | $625.00M | $739.00M | $758.00M | $778.00M | $341.00M |
| Prevymis | $376.00M | $416.00M | $430.00M | $416.00M | $456.00M | $532.00M | $552.00M | $272.00M |
| Alliance revenue - Lenvima | $499.00M | $502.00M | $509.00M | $516.00M | $531.00M | $516.00M | $543.00M | $256.00M |
| Janumet | $449.00M | $409.00M | $510.00M | $494.00M | $503.00M | $486.00M | $397.00M | $207.00M |
| RotaTeq | $326.00M | $386.00M | $278.00M | $456.00M | $242.00M | $408.00M | $239.00M | $206.00M |
| Vaxneuvance | $378.00M | $479.00M | $321.00M | $461.00M | $458.00M | $451.00M | $280.00M | $202.00M |
| Welireg | $252.00M | $278.00M | $319.00M | $275.00M | $324.00M | $392.00M | $441.00M | $199.00M |
| Alliance Revenue - Reblozyl | $180.00M | $200.00M | — | $238.00M | $214.00M | $272.00M | $326.00M | $148.00M |
| Capvaxive | — | — | — | $214.00M | $258.00M | $489.00M | $557.00M | $142.00M |
| Ohtuvayre | — | — | — | — | — | — | — | $131.00M |
| Keytruda Qlex | — | — | — | — | — | — | — | $128.00M |
| Zerbaxa | $123.00M | $129.00M | $140.00M | $140.00M | $148.00M | $162.00M | $174.00M | $82.00M |
| Adempas | $72.00M | $72.00M | $73.00M | $68.00M | $80.00M | $82.00M | $82.00M | $78.00M |
| Delstrigo | $119.00M | $130.00M | $137.00M | $134.00M | $167.00M | $154.00M | $157.00M | $75.00M |
| Isentress/Isentress HD | $178.00M | $204.00M | $184.00M | $180.00M | $172.00M | $163.00M | $135.00M | $59.00M |
| Dificid | $183.00M | $192.00M | $159.00M | $166.00M | $192.00M | $86.00M | $50.00M | $34.00M |
| Lagevrio | $110.00M | $383.00M | $121.00M | $102.00M | $83.00M | $138.00M | $57.00M | $28.00M |
| Belsomra | $106.00M | $156.00M | $89.00M | $100.00M | $79.00M | $94.00M | $99.00M | — |
| Companion Animals | — | — | $1.02B | — | — | — | $1.03B | — |
| Noxafil | $89.00M | $82.00M | $71.00M | — | — | — | — | — |
| Pifeltro | $78.00M | $85.00M | $79.00M | $90.00M | $82.00M | $86.00M | $83.00M | — |
| Pneumovax23 | $118.00M | $136.00M | $150.00M | $81.00M | $76.00M | $90.00M | $86.00M | — |
| Reblozyl | — | — | $185.50M | — | — | — | — | — |
| Remicade | $70.00M | $82.00M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Simponi | $344.00M | $378.00M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total | $16.11B | $16.66B | $15.62B | $15.53B | $15.81B | $17.28B | $16.40B | $16.29B |
Reblozyl is derived from annual filings.
Adempas, Alliance revenue - Lenvima, Alliance revenue - Lynparza, Alliance Revenue - Reblozyl, Alliance Revenue Adempas, Belsomra, Bridion, Capvaxive, Companion Animals, Delstrigo, Dificid, Gardasil/Gardasil 9, Isentress/Isentress HD, Janumet, Januvia, Keytruda, Keytruda Qlex, Lagevrio, Livestock, Noxafil, Ohtuvayre, Other pharmaceutical, Pifeltro, Pneumovax23, Prevymis, Primaxin, ProQuad/M-M-R II/Varivax, Reblozyl, Remicade, RotaTeq, Simponi, Vaqta, Vaxneuvance, Welireg, Winrevair, Zerbaxa were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceutical | $14.41B | $14.94B | $14.04B | $13.64B | $14.05B | $15.61B | $14.84B | $14.35B |
| Animal Health | $1.48B | $1.49B | $1.40B | $1.59B | $1.65B | $1.62B | $1.51B | $1.79B |
| Total | $16.11B | $16.66B | $15.62B | $15.53B | $15.81B | $17.28B | $16.40B | $16.29B |
Animal Health, Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Geographic Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Europe, Middle East and Africa | $3.52B | $3.58B | $3.38B | $3.45B | $3.66B | $3.68B | $3.79B | $3.89B |
| Latin America | $858.00M | $936.00M | $869.00M | $792.00M | $859.00M | $905.00M | $854.00M | $874.00M |
| Asia Pacific (other than China and Japan) | $748.00M | $823.00M | $763.00M | $689.00M | $785.00M | $764.00M | $745.00M | $738.00M |
| Other | $612.00M | $624.00M | $702.00M | $701.00M | $595.00M | $798.00M | $784.00M | $679.00M |
| Total | $16.11B | $16.66B | $15.62B | $15.53B | $15.81B | $17.28B | $16.40B | $16.29B |
Asia Pacific (other than China and Japan), Europe, Middle East and Africa, Latin America, Other were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Total Revenue at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s total revenue?
- Merck & Co. (MRK) reported total revenue of $16.29B in Q1 2026.
- How has Merck & Co.'s total revenue changed year-over-year?
- Merck & Co.'s total revenue increased by 4.9% year-over-year, from $15.53B to $16.29B.
- What is the long-term trend for Merck & Co.'s total revenue?
- Over 4 years (2021 to 2025), Merck & Co.'s total revenue has grown at a 7.5% compound annual growth rate (CAGR), from $48.70B to $65.01B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.